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We retrospectively analyzed SARS-CoV-2 vaccination antibody responses in a cohort of
273 patients with lymphoproliferative disorders or plasma cell dyscrasias who were seen
at a single tertiary cancer center. Semi-quantitative anti-spike protein serologic testing
was performed with enzyme immunoassay method. We found that the antibody response
rate to SARS-CoV-2 vaccination was 74.7% in our patient cohort with no difference based
on gender, age or race. The highest response rate was found in patients with Multiple
Myeloma (MM) (95.5%). The response rates found in Diffuse Large B-Cell Lymphoma
(DLBCL), Chronic Lymphocytic Leukemia (CLL), and Low-Grade Non-Hodgkin
Lymphoma (LG-NHL) were 73.2%, 61.5% and 53% respectively. We also evaluated
the effects of receiving active chemo-immunotherapy on SARS-CoV-2 vaccination
antibody response. We found that the patients on treatment had lower response than
the patients off treatment (62.1% versus 84.4% p<0.001). Thirty-four of 58 LG-NHL
patients were receiving anti-lymphoma treatment with a lower SARS-CoV-2 vaccination
response as compared to the patients who were not on treatment (29.4% v 87.5%
p<0.001). We observed a similar pattern in CLL patients receiving treatment (48.1 v 76.0
p:0.049). We found that only disease type and treatment status (on-treatment vs. off-
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treatment), but not gender, age or race were signiﬁcant predictors of non-response in the
multivariable logistic regression model. The interaction between disease type and
treatment status was not statistically signiﬁcant by multivariate analysis. In conclusion,
receiving anti-cancer treatment was found to play a signiﬁcant role in decreasing the
response to COVID-19 vaccination.
Keywords: vaccination, Covid-19, immune response, hematologic malignancies, chemotherapy.

population is immunocompromised (5). There are limited
published data available to establish SARS-CoV-2 vaccine safety
and efﬁcacy in these groups. However, the current FDA-approved/
authorized SARS-CoV-2 vaccines are not live vaccines and therefore
can be safely administered to immunocompromised people.
Patients with stable HIV infection were included in the SARSCoV-2 vaccine clinical trials, although the number of participants
were small. Reports of SARS-CoV-2 vaccine response in persons
living with HIV have shown lower response rates as compared to
the general population correlating with CD4+ count and degree of
viral suppression*. A study with 658 solid organ transplant (SOT)
recipients showed that only 98 (15%) of 658 subjects had a
measurable antibody response after dose 1; 259 (39%) of 658 had
no antibody response after dose 1 but subsequent antibody response
after dose 2; and 301 (46%) of 658 had no antibody response after
dose 1 or dose 2 (6). Assessments of a third full dose of SARS-CoV2 vaccine in SOT recipients have shown improved response rates,
albeit most notable in patients with an initial low level antibody
response after either the ﬁrst or second doses (7). The American
Society of Transplantation now recommends a third full dose of
mRNA vaccine in SOT recipients who have received two mRNA
vaccine doses or a second dose of any vaccine in those who have
received the J&J/Janssen vaccine (AST COVID-19 Vaccine FAQ
Sheet. https://www.myast.org/sites/default/ﬁles/11.14.21VaccineFAQ-Professionals.pdf). Additionally, recognizing that
immunocompromised patients may not respond as well to a two
shot series, the CDC recently recommended booster injection for
adult patients 8 months after completion of their second dose of the
Pﬁzer of Moderna vaccine.
Several studies have reported on SARS-CoV-2 vaccination
response in patients with cancer. Monin et al. demonstrated poor
antibody response after a single dose of the Pﬁzer mRNA vaccine
in cancer patients (8). 151 patients with cancer (95 patients with
solid cancers and 56 patients with hematological cancers) and 54
healthy controls were enrolled in the study. Positive anti-S IgG
titers at approximately 21 days following a single vaccine
inoculum across the three cohorts were 32 (94%; 95% CI 8198) of 34 healthy controls; 21 (38%; 26-51) of 56 patients with
solid cancers, and eight (18%; 10-32) of 44 patients with
hematological cancers. The response rate improved after the
second vaccination dose, which was given 21 days after the ﬁrst.
Another study from the University of Pittsburgh showed that
46% of patients with hematologic malignancies did not produce
antibodies after two doses of the mRNA vaccines (9). Patients
with Chronic Lymphocytic Leukemia (CLL) were at a
particularly high risk of not mounting an antibody response to
vaccination, as only 23% had detectable antibodies despite the

INTRODUCTION
In the United States, two messenger RNA (mRNA) vaccines and
an adenovirus vector-based vaccine have been granted
Emergency Use Authorization from the Food and Drug
Administration (FDA) for the prevention of the SARS-CoV-2
virus infection. The BNT162b2 (Pﬁzer/BioNTech) and the
mRNA-1273 (Moderna) Covid-19 vaccines have both been
shown in large phase III clinical trials to be more than 90
percent effective at preventing lab-conﬁrmed Covid-19 illness
and severe infections (1, 2). The single-dose recombinant,
adenovirus based vaccine (Ad26.COV2.S; Johnson & Johnson/
Janssen) reduced the incidence of symptomatic Covid-19 by 72%
in the large phase III clinical trial (3). The Pﬁzer/BioNTech
vaccine has subsequently been fully approved by FDA. These
other two SARS-CoV-2 vaccines (Moderna and J&J/Janssen) are
pending full FDA approval.

Immune Response to mRNA Vaccine
Generally, mRNA vaccines deliver speciﬁc mRNA into host
antigen presenting cells (such as dendritic cells). The majority
of mRNA vaccines are packaged in biodegradable lipid
nanoparticles (LNPs) consisting of phospholipids, cholesterol
and polyethylene glycol (PEG) (4). This LNP package protects
mRNA from degradation before translation. Vaccines that are
mRNA based do not need to enter the nucleus to be effective and
are not incorporated into the DNA. The mRNA vaccine interacts
with ribosomes and stimulates viral protein production, which in
this case is the Covid-19 spike protein. The speciﬁc protein
generated by the vaccine mRNA is processed by the endoplasmic
reticulum (ER) and proteasome system allowing viral peptides to
be presented on the cell surface with MHC molecules. Antigen
presentation leads to stimulation of T cells, especially helper T
cells. Helper T cell expansion and activation stimulate cytotoxic
T-cells (CD8+ T cells) and B cells. This process eventually
stimulates germinal centers in the lymph nodes, which results
in plasma cell proliferation and speciﬁc antibody production,
which in this case is anti-spike protein immunoglobulin (4).
Antibody levels against the spike protein can be measured in the
serum to assess immune response to vaccination. Assessment of
the T cell response to vaccination, another important component
of immune protection, is not as easily measured.

SARS-CoV-2 Vaccination in
Immunocompromised Patients
People with immunocompromising conditions may be at increased
risk of severe Covid-19. It is estimated that over 2% of the US
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treatment or have received in the last 3 months, are accepted as
on-treatment status.

fact that nearly 70% of these patients were not on cancer therapy.
Van Okelen and colleagues reported that most of fully
immunized patients with multiple myeloma mounted
measurable SARS-CoV-2 spike-binding IgG antibody levels
(84.2% (219/260)) (10). Moreover, patients receiving myeloma
treatment had signiﬁcantly lower SARS-CoV-2 spike-binding
IgG antibody levels after vaccination compared to patients not
receiving anti-myeloma therapy.
A recent study also evaluated SARS-CoV-2 vaccination
response in a large group of 1400 patients with hematological
malignancies from a prospective cohort registry study from
March to May 2021. Antibody levels were tested at a median
time of 42 days after receiving the 2nd vaccine (11). They found
that 75% of all patients with hematologic malignancies produced
antibodies to the SARS-CoV-2 mRNA vaccines. Patients with the
most common B cell malignancies had the lowest rate
of seropositivity.
In sum, several studies have shown that patients with
immunosuppressive comorbidities may mount suboptimal
antibody responses to SARS-CoV-2 immunization. This was
seen in cancer patients who are immunocompromised due to
defects in humoral and cellular immunity due to the underlying
malignancy as well as due to immunosuppressive therapy.
We assessed the antibody response to SARS-CoV-2
vaccination in our patients with lymphoproliferative disorders
and plasma cell dyscrasias to further evaluate this high-risk
population with impaired responses to other vaccines. We also
evaluated the effects of anti-cancer treatment on the response to
SARS-CoV-2 vaccination.
*: The study, “Lower SARS-CoV-2 IgG and pseudovirus
neutralization titers post-mRNA vaccination among people
living with HIV,” was presented virtually at IDWeek 2021, held
September 29-October 3, 2021.

Covid-19 Antibody Test
Semi-quantitative anti-spike (S) serologic testing was performed
with the Roche Elecsys anti-SARS-CoV-2 S enzyme
immunoassay, which tests for the receptor-binding domain of
S and correlates with neutralizing immunity mediated by
vaccination (12). The sensitivity and speciﬁcity of the
immunoassay is close to 100% for the detection of spike
antibodies in response to Covid-19 vaccine.
Roche Diagnostic reported that Elecsys Anti Sars-Cov-2 S
assay positive 225 of 233 samples were determined with > 0.8 U/
ml considered positive, resulting in a positive percent agreement
(PPA) of 99.6. (95% CI: 93.95-98.51) in the cohort. Speciﬁcity is
reported 99.80 (95% CI 99.69-99.88%). Sensitivity was found as
85.3 (78.6 -90.6) 7-13 days after PCR conﬁrmation and 99.5%
(CI 97.0-100%) 14 days after PCR conﬁrmation. Source:
Roche Diagnostic
https://diagnostics.roche.com/us/en/products/params/
elecsys-anti-sars-cov-2.html. We used 0.4 U/ml as cut-off for
antibody response per our laboratory.
Patients positive for the anti-nucleocapsid antibody
indicating a prior exposure to SARS-CoV-2, were included for
the data analysis as long as they had completed the vaccination
schedule for SARS-CoV-2.

Statistical Analysis
The proportion of patients who developed a positive antibody
response to the anti-S antibody was compared between patient
characteristic groups and disease and treatments categories using
the Fisher exact test and its extension (for more than 2 groups).
All tests were two-sided, with a = 0.05. The multivariable logistic
regression model was used to model the odds of non-response as
dependent on patient characteristic groups and disease and
treatments categories. Non-response was selected as outcome
for the logistic regression model because the response was more
prevalent than non-response. Disease type, gender, age group
(<65 vs. 65+), race (dichotomized as white vs. non-white), and
treatment status (on- treatment vs. off- treatment) were
considered as predictors of non-response. The interaction
between disease type and treatment status was also considered.
The ﬁnal model includes only signiﬁcant (at the level 0.05)
predictors. Statistical analyses were performed in R (R Core
Team (2021). R: A language and environment for statistical
computing. R Foundation for Statistical Computing, Vienna,
Austria. URL https://www.R-project.org/.).
The study was approved by the Institutional Review Board of
Thomas Jefferson University.

MATERIALS AND METHODS
Study Characteristics
This is a retrospective cohort study. We aimed to evaluate Covid19 vaccination response in patients with hematologic
malignancies including lymphoproliferative disorders and
plasma cell dyscrasias.

Patient Population
We retrospectively analyzed adult patients who are older than 18
years old with lymphoproliferative disorders or plasma cell
dyscrasias seen in our tertiary care cancer center from January
1, 2021 to August 10, 2021. We collected data including age, sex,
cancer diagnosis, treatments, prior Covid-19 infections, vaccine
type and dates of administration. The antibody response was
assessed a minimum of 2 weeks after the second dose of the
mRNA vaccines or 3 weeks from the one dose of the J&J vaccine.
Off-treatment and on-treatment: The patients who have not
received any treatment for at least the last 3 months, are accepted
as off-treatment status. If the patients who are actively receiving
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We retrospectively analyzed a cohort of 273 patients with a
diagnosis of a lymphoproliferative disorder or plasma cell
dyscrasia who had been seen at the Sidney Kimmel Cancer
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Center of Thomas Jefferson University Hospital from January 1
to August 10, 2021. 93 female and 180 male patients were
enrolled with a median age of 67 years (27-94). Total response
rate to SARS-CoV-2 vaccination was 74.7%. Sixty-nine of these
patients did not have increased titers (25.3%). The age does not
affect the Covid-19 vaccination response. There was no
signiﬁcant difference in vaccine response between patients
older than 65 and those younger than 65 years (p=057).
Response rates also did not differ on the basis of gender, with
71.8% response in males and 81.7% response in females
(p=0.058) (Table 1).

than the non-seroconverters (91.5 ± 6.5 versus 77.4 ± 9.6 days,
P< 0.05). Therefore, the longer interval from the last vaccination
did not affect the response to the covid-19 vaccine in our study.

Subtype of Disease
We evaluated patients in ﬁve different disease categories including;
i) chronic lymphocytic leukemia (CLL), ii) low grade B cell
lymphoma-LG-NHL (follicular lymphoma (FL), marginal zone
lymphoma, and Waldenstrom macroglobulinemia etc.), iii) diffuse
large B cell lymphoma (DLBCL), iv) multiple myeloma (MM) and
plasma cell dyscrasias, v) remaining other patients (OP). The details
of the groups are given as follows

Race

Multiple Myeloma/Plasma Cell Dyscrasias Group

This cohort included Caucasian patients [212 patients (78%)],
African American-AA patients (46 patients, 16.8%), hispanic
patients (5 patients, 1.8%) and Asian American (10 patients,
2.9%). There was no signiﬁcant difference in SARS-CoV-2
vaccination antibody responses in Caucasian versus African
American patients (75%, versus 78.3% respectively, p>0.05) or
between the Caucasian group compared to all patients belonging
to minority groups (75% v 73.8% respectively; p=0.86)).

Consists of 41 patients with multiple myeloma, 12 patients with
MGUS, ﬁve patients with smoldering myeloma (SM), ﬁve patients
with amyloidosis, and three patients with plasmacytoma. Eighteen
patients underwent autologous stem cell transplantation. One
patient had a transplant in the last six months prior to
vaccination. Five of them had a transplant in the last 12 months
prior to vaccination. Most of the transplanted patients have been
on maintenance treatment, including lenalidomide (8/18, 44%),
bortezomib (3/18, 16.6%), and daratumumab (2/18, 11.1%). As
expected, most myeloma patients were on active treatment. The
patients with MGUS, SM, and amyloidosis were off treatment.

Type of the Vaccine
Vaccine type was available for 267 patients. Seventy-nine
patients received the Moderna vaccine of whom 69 had a
response (83.5%). Looking at the overall response to the Pﬁzer
vaccine, out of a total of 179 patients, 131 patients (73.2%) had a
response. Six patients received the J&J vaccine of which 83.4%
achieved a response. Moderna vaccine response was higher than
Pﬁzer vaccine response, but was not statistically signiﬁcant (p:
0.06, Relative risk: 1.15. (CI: 0.98 to 1.30)

DLBCL Group
We have 41 patients in this group. Six patients are on active
treatment. Six patients have completed treatment in the last six
months prior to vaccination. 23 of 41 (56%) patients did not have
any treatment in the last 12 months. Three patients completed
treatment in the last 12 months. Only 3 patients underwent
autologous stem cell transplantation. One of them had a
transplant in the last 12 months. The other two patients had a
transplant greater than one year prior to vaccination.

Intervals From the Vaccination
The median duration between two vaccinations is three weeks
for Pﬁzer/BioNTech and four weeks for Moderna as
recommended. We evaluated the interval between the last
Covid-19 vaccination and the sample collection for antibody
response. We found that the responders had a longer duration

LG-NHL
This group includes patients with follicular lymphoma, marginal
zone lymphoma, Waldenstrom macroglobulinemia, and mantle
cell lymphoma. Thirty-four patients were on treatment. Two
patients completed the chemotherapy (R-CHOP) in the last six
months. Two patients had autologous SCT, and one of them was
performed in the last 12 months. The patients receive multiple
chemotherapies in combination with anti-CD20 antibodies.
Eleven of 34 (32.3%) patients receive a combination of
ibrutinib and obinutuzumab. In addition, rituximab has been
given to eight patients as a single agent (8/34, 23.5%). Twent-four
patients were off treatment.

TABLE 1 | The response rates to Covid-19 vaccination.
Characteristics
Gender
Female
Male
Age
<65
>=65
Treatment
On treatment
Off treatment
RACE
White
NonWhite
AA
Hispanic
Asian

Response

%

P Value

76/93
128/180

81.7
71.1

0.058

86/112
118/161

76.8
73.3

0.572

74/119
130/154

62.1
84.4

<0.001

159/212
45/61
36/46
4/5
5/10

75.0
73.8
78.3
80.0
50.0

CLL Group
Fifty-two patients are in this group. Twenty-seven patients
received treatment, including ibrutinib 10/27 (37%).
Obinutuzumab and venetoclax combination is the second most
frequently used regimen for patients with CLL (6/27, 22%).
Twenty-ﬁve patients were off treatment. None of the CLL
patients underwent stem cell transplant or cellular therapy in
the last twelve months.

0.868 (*)

(*) comparing response rates between non-White and White.
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TABLE 2 | The response rates to Covid-19 vaccination according to disease.
Disease

Response (+)

%

Total

DLBCL
LG-NHL
Myeloma
CLL
Other*
Total

30
31
63
32
48
204

73.2**
53.4
95.5
61.5
85.7
74.7%

41
58
66
52
56
273

response to Covid-19 vaccination (48%). The response rate was
signiﬁcantly higher at 76% in untreated CLL patients (p=0.049).
However, we did not ﬁnd a statistically signiﬁcant difference in
the multivariate analysis model in disease-speciﬁc groups.
Overall, receiving treatment signiﬁcantly affects to response to
Covid-19 vaccination.
We also found that the type of anti-cancer treatment was
associated with response to SARS-CoV-2 vaccination. We
combined both the CLL and LG-NHL groups to study
treatment effects. BTK inhibitors in CLL and LG-NHL
moderately decreased antibody responses to vaccination. Out of
110 patients in these 2 groups, 61 patients were on active anticancer treatment. Fourteen patients, who were on ibrutinib alone
had a 50% response rate to the Covid-19 vaccination, which was
similar to the overall CLL/LG-NHL group (57%). The response
rate in the treatment group was only 38%, which was statistically
signiﬁcant different from the non-treatment group (81.6%,
P<0.001). Interestingly, the patients who had received ibrutinib
and obinutuzumab combination had only a 9.1% response rate to
the SARS-CoV-2 vaccination (Figure 1), which is signiﬁcantly
lower than the ibrutinib alone group. Other patients with
obinutuzumab combinations had a similar response rate (10%).
The patients who received rituximab or rituximab containing
combinations showed a trend towards higher responses to
vaccination (40%), than patients with obinutuzumab containing
protocols (9.5%). Interestingly, 5 patients who had been receiving
only IVIG, responded well to COVID-19 vaccination (100%).

*Other: Hodgkin’s lymphoma, peripheral T cell lymphoma (PTCL), large granular
lymphocytosis (LGL), lymphoproliferative disease, cutaneous T cell lymphoma (CTCL),
Post-transplant lymphoproliferative disease (PTLD), Castleman disease etc.
**The overall difference in response rate is signiﬁcant (p<0.001), showing differences in
response rates between disease groups.

The response rates to SARS-CoV-2 vaccination are shown in
Table 2. The highest response rate was found in patients with
MM (95.5%). Response rates were 73.2% in DLBCL, 53.4% in
low-grade lymphoma, 61.5% in CLL and 86% in OP. When we
compared the groups, we found that the multiple myeloma
group showed a better response than all other groups. There
was a trend in the DLBCL group to have an increased antibody
response rate compared to the LG-NHL group, but it was not
statistically signiﬁcant.(p=0.059).

Effects of Treatment
We found that receiving active chemo-and/or immunotherapy
was associated with an impaired SARS-CoV-2 vaccination
response especially in low-grade lymphoma and CLL patients.
Thirty-four of 58 LG-NHL patients had received anti-lymphoma
treatment including rituximab, obinutuzumab alone or in
combination with chemotherapy, or Bruton Tyrosine Kinase
(BTK) inhibitors at the time of their vaccinations. If the
patients have received treatment in the last three months
before the vaccination, in addition to the patients who are
actively on treatment, they were accepted as active treatment.
The antibody response to SARS-CoV-2 vaccination in patients
receiving therapy was 10 of 34 patients (29.4%). The patients
who were not on any treatment showed a signiﬁcantly better
response to vaccination (87.5%) compared to the patients who
were receiving treatment (p<0.001), which is shown in Table 3.
We observed a similar pattern in CLL patients. Thirteen of 27
patients with CLL that received treatment have an antibody

Results From the Multivariable Logistic
Regression Model for NON-Response
Considered jointly, only disease type and treatment status (ontreatment vs. off- treatment), but not gender, age group or race
were signiﬁcant predictors of non-response in the multivariable
logistic regression model. In comparison to Myeloma patients
with the highest response rate (Table 2), all other disease types
had signiﬁcantly higher odds of non-response (Table 4). That is,
the odds of non-response were estimated to be 16.3 times higher
for CLL (95%CI: 5.0-74.8; p<0.001), 16.6 times higher for
DLBCL (95%CI: 4.4-82.9; p<0.001), 21.4 times higher for LGL
(95%CI: 6.7-96.7; p<0.001), and 5.9 times higher for other
category (95%CI: 1.5-29.0; p=0.014). The odds of non-response

TABLE 3 | The COVID-19 response rate by disease group on/off treatment.
Disease
CLL-off treatment*
CLL on treatment
Myeloma off treatment*
Myeloma on-treatment
DLBCL off treatment*
DLBCL on-treatment
LG-NHL-off treatment*
LG-NHL-on treatment
Other off treatment*
Other on-treatment

Response (+)

%

Total

p-value (#)

19
13
26
37
26
4
21
10
39
9

76.0%
48.1%
92.9%
97.4%
74.2%
66.6%
87.5%
29.4%
92.9%
64.3%

25
27
28
38
35
6
24
34
42
14

0.049
0.570
0.65
0.001
0.018

*Testing the patients who have not received any treatment for at least in the last 3 months.
#
Testing the difference between off treatment and on treatment response rates in each disease group.
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(p>0.05)*. We then evaluated non-paraprotein immunoglobulin
(IG) levels in the myeloma group. We found a reduction in nonparaprotein IG levels in 37 patients (non-paraprotein IG group).
The chance of developing antibody response with high titers is
similar in the non-paraprotein IG group and the patients with
normal IG (68.75 versus 60.0% P>0.05).
(* If antibody titer against the SARS-CoV-2 spike protein is
reported as higher than the maximum limits of laboratory values,
it is accepted as high-titer. Remaining positive titers are accepted
as low titers.)
We also compared absolute lymphocyte count (ALC) levels
between the two groups and found no difference in the high and
low titer groups (1389 ±105/mm3 versus 1266 ±152, respectively,
P>0.05). Interestingly, ALC levels are similar in the LG-NHL and
myeloma groups (1332 ± 99 versus 1345 ±100)

were 4.2 times higher (95%CI: 2.2-8.2; p<0.001) on-treatment as
compared to off- treatment. The interaction between disease type
and treatment status was not statistically signiﬁcant, but the
overall effect of treatment status appears to be important in CLL,
LGL and other disease types (Table 3).

The Effects of Immunoglobulin Levels and
Absolute Lymphocyte Count
We ﬁrst evaluated the patients with low-grade lymphoma and
CLL. We routinely check immunoglobulin levels in this patient
population. The patients with Waldenstrom Macroglobulinemia
are excluded from the analysis. Seventeen patients with LG-NHL
or CLL (17 of 102 patients) had hypogammaglobulinemia (all
three Immunoglobulins (IG) IgG, IgA, and IgM levels were lower
than normal levels) prior to the vaccination. Their response to
the vaccination is 35.2%, lower than the remaining LG-NHL/
CLL patients’ response (61%, P: 0.06, relative risk 0.57 (CI:
0.27-0.99).
We then look at the myeloma group. We found that nine
patients with hypogammaglobulinemia had decreased response.
Since most of the patients have responded well to vaccination, we
have looked at titers of antibody response in the myeloma
patients. We found that there is no difference in the risk of
developing hypogammaglobulinemia between patients with high
titers 6/34 (17.6%) and the patients with low titers 3/19 (15.7%)

DISCUSSION
In this retrospective analysis, we evaluated 273 patients with
lymphoproliferative disorders and plasma cell dyscrasias and
observed that they had a decreased response to SARS-CoV-2
vaccination especially those with CLL and LG-NHL who had
been receiving anti-cancer therapy. We consider that receiving

FIGURE 1 | Effects of anti-cancer treatment on SARS-CoV-2 vaccination response. Obi, Obinutuzumab; Obi-Comb, Obinutuzumab+Venetoclax or Obinituzumab
+venetoclax+ibrutinib.

TABLE 4 | Results from the multivariable logistic regression model for NON-response to Covid-19 vaccination.
Odds

95% conﬁdence interval

Comparison

Ratio

Lower Limit

Upper Limit

p-value

CLL vs. Myeloma
DLBCL vs. Myeloma
LGL vs. Myeloma
Other vs. Myeloma
On-Tx vs. Off-Tx

16.3
16.6
21.4
5.9
4.2

5.0
4.4
6.7
1.5
2.2

74.8
82.9
96.7
29.0
8.2

<0.001
<0.001
<0.001
0.014
<0.001
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greater than 9 months after completion of anti-CD20 therapy. In a
cohort of four lymphoma subgroups, which included patients on
active treatment or within 3 months after completion of treatment,
patients that were 3 to 6 months post-anti-CD20 treatment, patients
between 6 and 9 months post-anti-CD20 treatment, and patients
that were more than 9 months after CD20–directed therapy, it was
found that none of the patients demonstrated a signiﬁcant IgM
response to the vaccination (20). The IgG response in patients with
ongoing treatment or vaccinated within 3 months from the last
treatment was signiﬁcantly lower than patients vaccinated more
than 9 months after the last treatment. Their study suggested that
SARS-CoV-2 vaccination at least 9 months from the last B celldirected treatment might result in improved antibody titers. Despite
these ﬁndings, the optimal timing of vaccine administration post
treatment is unknown. While some have postulated that patients
may still beneﬁt from cellular immunity in the absence of humoral
immunity, recent studies have demonstrated that these two immune
responses tend to correlate well in terms of response to the COVID19 mRNA vaccines (21). Taken together these studies suggest we
should wait 6-9 months post B-cell directed therapy to get
vaccinated, but further data with larger cohorts of patients is still
needed to conﬁrm these preliminary results.
Marchesi et al. found that patients receiving the SARS-CoV2
vaccines during treatment with anti-CD20 agents did not mount
an antibody response to the vaccine. However some patients
started to mount an antibody response if vaccinated at least 3
months after completion of anti-CD20 therapy (22). In our
study, if the patient receives anti-CD20 antibody infusion in 3
months before the Covid-19 vaccination, is included to active
treatment group.
A study by Greenberger et al. showed similar ﬁndings to our
study in terms of a decreased vaccine response in lymphoma
patients (11). The investigators evaluated leukemia, lymphoma
and myeloma patients from a prospective cohort registry study
from March to May 2021. Antibody levels were tested at a
median time of 42 after receiving the 2nd vaccine. In patients
with B-cell malignancies, seronegativity was observed in almost
all non-Hodgkin Lymphoma subtypes while all but one of 64
Hodgkin lymphoma patients were seropositive. Their analysis
showed that patients with the most common B cell malignancies
including CLL, FL, DLBCL and mantle cell lymphoma have the
lowest rate of seropositivity (44% - 79%). Interestingly, we have
not found the same pattern of reduced antibody responses in
patients with multiple myeloma (MM) on anti-cancer treatment
that we observed in LG-NHL and CLL patients receiving anticancer therapy. Eighteen out of 67 MM patients were on
Lenalidomide and/or Bortezomib and all responded to SARSCoV-2 vaccination. Hence, patients with MM on lenalidomide
and/or bortezomib treatment had good antibody responses to
SARS-CoV-2 vaccination in our study. Similarly, the study
published by Greenberger et al. reported that 95.1% of
myeloma patients responded well to Covid-19 vaccination (11).
A recent study published in Cancer Cell, showed a slightly lower
SARS-CoV-2 vaccination response in MM patients compared to
our study. 320 MM patients were tested for an antibody response
10 days after the 2nd vaccine dose of the Pﬁzer or Moderna

anti-CD20 antibody results in a decreased antibody response
to vaccination.
Anti-CD20 antibody treatment decreases the immune function.
B cell count rapidly declines after anti-CD20 antibody (rituximab)
therapy and slowly recovers over six months and requires
approximately one year for complete restoration (13). Rituximab
monotherapy did not signiﬁcantly affect on CD3+, CD4+, and
CD8+ T-cell counts. Anolik et al. reported a sustained increase in
the percentage of transitional B cells and a slow increase in the
number of memory B cells, which remained at very low levels even
at one year after rituximab treatment (14). Rituximab use also
decreases immunoglobulin production. The MSKCC lymphoma
group evaluated serum IgG levels before and after rituximab
therapy. After rituximab therapy, hypogammaglobulinemia was
identiﬁed in 39% of patients with initially normal serum IgG
levels (15). Symptomatic hypogammaglobulinemia, including
sinopulmonary infections, prompted a start of IVIG administrations
in 6.6% of the patients. Makatsori et al. from the UK found signiﬁcant
hypogammaglobulinemia in patients treated with rituximab. All
patients had reduced or absent B-cells after anti-CD20 therapy.
Haemophilus Inﬂuenzae B, tetanus and pneumococcal serotypespeciﬁc antibody levels were all reduced, and patients failed to mount
an immune response post-vaccination (16).
Treatment with an anti-CD20 monoclonal antibody has
negatively affected antibody response after inﬂuenza
vaccination in lymphoma patients. Yri et al. reported that
lymphoma patients who are undergoing treatment with
rituximab-containing regimens or have received such regimens
within the past six months were unable to mount protective
antibody responses to the inﬂuenza A (H1N1) 2009 virus vaccine
(Pandemrix) during the 2009 “swine ﬂu” pandemic (17). Sixtyseven lymphoma patients and 51 healthy controls were enrolled
in their study. Although 82% of the control group responded
adequately to the vaccine, none of the 67 patients in the
treatment arm achieved protective antibody titers. The median
value of immunoglobulins, CD3+, CD4+, and CD8+ cell counts
were within normal ranges in the patients. CD19+ B cells were
undetectable in most of patients in the lymphoma group. We
should consider that anti-CD20 treated patients might fail to
respond not only to the inﬂuenza vaccine but also to other
vaccines, including the Covid-19 vaccines.
Houot et al. showed negative effects of anti-CD20 antibodies
on vaccine efﬁcacy before the development of SARS-CoV-2
vaccines (18). Our study suggests that obinutuzumab may
more profoundly decrease the SARS-CoV-2 vaccine response
in patients with LG-NHL or CLL. Care needs to be exercised in
using anti-CD20 antibodies during pandemics and alternative
treatment options may need to be considered.
Gurion and colleagues reported the importance of timing of
vaccination after anti-CD20 treatment to generate an antibody
response to SARS-CoV-2 vaccination. They found that the
antibody response to the BNT162b2 vaccine is reduced in
lymphoma patients within the ﬁrst 12 months following
treatment with anti-CD20 antibodies (19). Other groups have also
studied the effects of time from last anti-CD20 infusion to
vaccination. The antibody response was improved if vaccinated
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consider in patients with low-grade B cell lymphomas and CLL
are to discuss the risks and beneﬁts of using anti-CD20 antibody
therapies and the administration of prophylactic passive
immunization with anti-SARS-CoV-2 monoclonal antibodies.
The efﬁcacy of Covid-19 vaccination may affect the outcome of
Covid-19 infection, the rate of hospital admission due to Covid19 and the overall survival of the patients, which will be
investigated in the larger prospective clinical studies.

vaccines and 84.2% of the patients were found to have a response
after vaccination (10). Furthermore, they found that 58.5% of
non-responders were on anti-CD38 antibody-containing therapy
at the time of vaccination, 31.7% were on anti-BCMA bispeciﬁc
antibody therapy, and 9.8% had undergone anti-BCMA CAR-T
therapy more than three months prior. The study showed that
MM patients receiving anti-CD38 or BCMA-targeted therapies
had lower antibody levels.
Multiple myeloma is commonly associated with reducing of
the serum levels of polyclonal immunoglobulins and the failure to
synthesize a suitable antibody response following immunization.
Immunoparesis is deﬁned as reducing at least one uninvolved
immunoglobulin level below the normal levels in patients with
myeloma/plasma cell dyscrasias (23). Our data showed that
immunoparesis does not affect antibody response after Covid-19
vaccination. The effect of immunoparesis on the outcome of
myeloma is not clearly documented, which may impact through
a combination of being associated with more aggressive disease
and reduced immune surveillance of myeloma (24). On the other
hand immunoglobulin replacement therapy appears to be one of
the reasonable approaches for the treatment of immunodeﬁciency
in patients with myeloma. Vacca et al. administered subcutaneous
IVIg administration to prevent infectious complication in patients
with myeloma in randomized clinical trial (25). It might be an
alternative approach for patients who do not respond well to
Covid-19 vaccination.
We consider that the study has several limitations, including
the retrospective nature, no assessment of cellular responses, and
lack of information on cumulative exposure and duration of
corticosteroids and immunomodulators.
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